Axon Enterprise (NASDAQ:AXON) Announces Quarterly Earnings Results

Axon Enterprise (NASDAQ:AXON) released its quarterly earnings results on Tuesday. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46), Briefing.com reports. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. During the same period in the prior year, the firm posted $1.45 EPS. The business’s revenue for the quarter was up 30.6% on a year-over-year basis. Axon Enterprise updated its Q4 2025 guidance to EPS and its FY 2025 guidance to EPS.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $706.13 on Wednesday. The firm has a fifty day moving average of $729.01 and a two-hundred day moving average of $736.07. The stock has a market capitalization of $55.43 billion, a price-to-earnings ratio of 174.35, a PEG ratio of 29.49 and a beta of 1.41. Axon Enterprise has a 52 week low of $433.97 and a 52 week high of $885.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95.

Analyst Ratings Changes

A number of research firms have recently weighed in on AXON. Morgan Stanley set a $885.00 price objective on Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. Northland Securities set a $800.00 price objective on Axon Enterprise in a research report on Tuesday, August 5th. JPMorgan Chase & Co. raised their target price on Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research note on Thursday, July 17th. UBS Group restated a “neutral” rating and issued a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Finally, JMP Securities restated a “market outperform” rating and issued a $825.00 target price on shares of Axon Enterprise in a research note on Monday, September 29th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $841.64.

Insider Activity at Axon Enterprise

In related news, President Joshua Isner sold 15,919 shares of the company’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the completion of the sale, the president owned 238,379 shares in the company, valued at $177,892,712.54. This represents a 6.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Jennifer H. Mak sold 77 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $760.00, for a total transaction of $58,520.00. Following the completion of the sale, the chief accounting officer owned 15,003 shares of the company’s stock, valued at approximately $11,402,280. This represents a 0.51% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 59,932 shares of company stock worth $45,115,616. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXON. AQR Capital Management LLC increased its holdings in shares of Axon Enterprise by 223.2% during the second quarter. AQR Capital Management LLC now owns 63,012 shares of the biotechnology company’s stock worth $51,680,000 after purchasing an additional 43,516 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in shares of Axon Enterprise by 26.9% during the second quarter. CANADA LIFE ASSURANCE Co now owns 86,503 shares of the biotechnology company’s stock worth $71,688,000 after purchasing an additional 18,362 shares during the period. BI Asset Management Fondsmaeglerselskab A S increased its holdings in shares of Axon Enterprise by 76.9% during the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 25,472 shares of the biotechnology company’s stock worth $21,089,000 after purchasing an additional 11,072 shares during the period. Canada Pension Plan Investment Board increased its holdings in shares of Axon Enterprise by 13.4% during the second quarter. Canada Pension Plan Investment Board now owns 89,985 shares of the biotechnology company’s stock worth $74,502,000 after purchasing an additional 10,638 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its holdings in shares of Axon Enterprise by 16.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 76,700 shares of the biotechnology company’s stock worth $63,503,000 after purchasing an additional 10,600 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.